Table 1 Patient, transplant characteristics and GVHD
Other gender combination (n = 421) | Female UCB to male recipient (n = 131) | Pvaluea | |
|---|---|---|---|
Median patient age, years (range) | 43 (18–70) | 42 (18–67) | 0.48 |
Median year of SCT, years (range) | 2009 (2000–2013) | 2009 (2000–2013) | 0.24 |
Recipient M donor F, # (%) | 0 (0) | 131 (100) | / |
Recipient M donor M, # (%) | 119 (28) | 0 (0) | |
Recipient F donor F, # (%) | 157 (37) | 0 (0) | |
Recipient F donor M, # (%) | 145 (34) | 0 (0) | |
Median time from diagn to SCT, days | 210 | 231 | 0.48 |
Secondary AML, # (%) | 72 (17) | 18 (14) | 0.36 |
Status at transplantation, # (%) | |||
CR1 | 233 (55) | 59 (45) | 0.12 |
CR2+ | 92 (22) | 36 (27) | |
Advanced | 96 (23) | 36 (27) | |
Cytogenetics, # (%) | |||
Good riskb | 17 (9) | 14 (21) | 0.005 |
Intermediate riskc | 56 (29) | 26 (39) | |
High riskd | 47 (25) | 8 (12) | |
Not reported/failed | 229 | 65 | |
Secondary AML | 72 (37) | 18 (27) | |
Recipient CMV-seronegative, # (%) | 100 (28) | 26 (27) | 0.83 |
Conditioning regimen, # (%) | |||
Myeloablative | 271 (65) | 94 (76) | 0.03 |
Reduced-intensity | 145 (35) | 30 (24) | |
ATG, # (%) | 232 (61) | 65 (56) | |
TNC at infusion ×107/kg | |||
Median (range) | 2.8 (0.33–40.3) | 2.5 (0.4–6.10) | 0.01 |
Missing data (# of patients) | 71 | 19 | |
Number of HLA disparities, # (%) | |||
0–1 mismatch | 121 (36) | 35 (33) | |
2–3 mismatches | 213 (64) | 70 (67) | 0.59 |
Missing data | 87 | 26 | |
Postgrafting immunosuppression, # (%) | |||
CSP alone | 140 (33) | 51 (39) | 0.19 |
CSP + MMF | 215 (51) | 55 (42) | |
Other/missing | 66 (16) | 25 (19) | |
Acute GVHD, # (%) | |||
Grades I–IV | 171 (43) | 59 (49) | 0.28 |
Grades II–IV | 99 (25) | 40 (33) | 0.08 |
Grades III–IV | 43 (11) | 18 (15) | 0.23 |
CI chronic GVHD @ 2 years, % | 28 | 21 | 0.44 |
Death from GVHD, # (%) | 29 (7) | 10 (8) | 0.77 |